NDLI: Harnessing synthetic lethal interactions in anticancer drug discovery.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Chan, Denise A. Giaccia, Amato J.
Description	Country affiliation: United States Author Affiliation: Chan DA ( Department of Radiation Oncology, University of California, San Francisco, California 94143-1331, USA.)
Abstract	Unique features of tumours that can be exploited by targeted therapies are a key focus of current cancer research. One such approach is known as synthetic lethality screening, which involves searching for genetic interactions of two mutations whereby the presence of either mutation alone has no effect on cell viability but the combination of the two mutations results in cell death. The presence of one of these mutations in cancer cells but not in normal cells can therefore create opportunities to selectively kill cancer cells by mimicking the effect of the second genetic mutation with targeted therapy. Here, we summarize strategies that can be used to identify synthetic lethal interactions for anticancer drug discovery, describe examples of such interactions that are currently being investigated in preclinical and clinical studies of targeted anticancer therapies, and discuss the challenges of realizing the full potential of such therapies.
File Format	HTM / HTML
ISSN	14741776
e-ISSN	14741784
DOI	10.1038/nrd3374
Journal	Nature Reviews Drug Discovery
Issue Number	5
Volume Number	10
Language	English
Publisher	Nature Publishing Group
Publisher Date	2011-05-01
Publisher Place	Great Britain (UK)
Access Restriction	Open
Subject Keyword	Discipline Pharmacology Discipline Biotechnology Antineoplastic Agents Pharmacology Drug Delivery Systems Neoplasms Drug Therapy Animals Cell Survival Genetics Drug Design Drug Discovery Drug Screening Assays, Antitumor Genes, Lethal Genes, Synthetic Research Support, N.i.h., Extramural Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Medicine Drug Discovery Pharmacology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Anticancer drug development: the grand challenges.

Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?

Cellular uptake and anticancer activity of carboxylated gallium corroles

The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Colorectal cancer models for novel drug discovery.

A phenotypic screening approach to identify anticancer compounds derived from marine fungi.

MicroRNAs and other non-coding RNAs as targets for anticancer drug development.

In vivo anticancer activity of rhomboidal Pt(II) metallacycles.

Synthesis of new 1,3,4-benzotriazepin-5-one derivatives and their biological evaluation as antitumor agents.

Harnessing synthetic lethal interactions in anticancer drug discovery.

Similar Documents

Anticancer drug development: the grand challenges.

Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?

Cellular uptake and anticancer activity of carboxylated gallium corroles

The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Colorectal cancer models for novel drug discovery.

A phenotypic screening approach to identify anticancer compounds derived from marine fungi.

MicroRNAs and other non-coding RNAs as targets for anticancer drug development.

In vivo anticancer activity of rhomboidal Pt(II) metallacycles.

Synthesis of new 1,3,4-benzotriazepin-5-one derivatives and their biological evaluation as antitumor agents.

Harnessing synthetic lethal interactions in anticancer drug discovery.